Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2025—In the 2024 edition of the CAP accreditation checklists, released on Dec. 26, laboratories can expect to see small but significant changes to the all common, cytopathology, and microbiology checklists. These revisions and additions are meant to ensure test quality as more laboratories begin to offer primary HPV screening and p16/Ki-67 dual stain triage.
January 2025—Pathology informatics leaders at the University of Michigan are moving in steps to a fully digital practice as they put in place an innovative workflow for primary diagnosis. Fresh off their August launch of the new workflow program within their remodeled histology lab, informatics directors in the pathology department say Michigan Medicine is the first in the U.S. to have radiology and pathology operating in the same shared picture archiving and communication system, or PACS, and to implement the well-established DICOM standard for pathology workflow.
January 2025—The point-of-care checklist in the 2024 accreditation checklist edition, released Dec. 26, now includes requirements on coagulation specimen collection and handling.
January 2025—A study published last year found variability in the variants tested for in the commercial lab DPYD genotyping assays available at the time of the study, underscoring “the importance of comprehensive DPYD genotyping to accurately identify patients with DPD deficiency,” the authors said. Compromised dihydropyrimidine dehydrogenase deficiency raises a cancer patient’s risk of fluorouracil toxicity.
January 2025—Whether grade group 1 prostate cancer should be renamed to “noncancer” was the center of debate on a CAP podcast last fall led by Gladell P. Paner, MD, in discussion with Ming Zhou, MD, PhD, and Rajal B. Shah, MD. Dr. Paner is professor of pathology and surgery, University of Chicago Pritzker School of Medicine, and director of the genitourinary pathology service and of the reproductive endocrinology and infertility laboratory, UChicago Medicine.
January 2025—A clinical laboratory team at Ohio State University Wexner Medical Center took on a point-of-care testing problem common to other hospitals: documentation of critical result notification. At OSU, the documentation rate for point-of-care glucose critical result notification wasn’t high enough, and the team set out to raise it. It’s not sufficient to notify the physician or other provider. “You then have to prove you’re doing this, with documentation that the notification did in fact exist,” said Heather Stieglitz, PhD, D(ABCC), OSU co-director of clinical chemistry and toxicology, in an ADLM point-of-care testing session last summer.
January 2025—Renal mass biopsy has become an indispensable pre-management diagnostic tool, especially as incidental renal masses are increasingly detected with modern imaging techniques. It offers the patient the opportunity to get a definitive diagnosis without necessitating nephrectomy, especially helpful for patients with advanced disease or those who are poor surgical candidates. This is crucial, as certain renal cell carcinoma (RCC) subtypes have significantly different prognostic outcomes and therapeutic implications, making it essential to subtype RCCs in addition to distinguishing between benign and malignant lesions. For instance, systemic treatment strategies diverge markedly between clear cell RCC and non-clear cell RCC subtypes, underscoring our role in guiding personalized therapy choices. This article synthesizes key findings and diagnostic challenges most encountered on renal mass biopsy, with a focus on clear cell RCC, clear cell papillary renal cell tumor, TFE3-rearranged RCC, papillary RCC, oncocytoma, and chromophobe RCC.
January 2025—It is well documented that the cytologist/cytotechnologist workforce is diminishing and the number of training programs has declined. According to the Centers for Medicare and Medicaid Services, CT participation in gynecologic proficiency testing has decreased by 27 percent since 2005. New board certifications of CTs or specialists in CT(SCT) decreased by about 56 percent over the same period. CT(ASCP) and all SCT(ASCP) certifications are now recognized by the CMS and the Centers for Disease Control and Prevention per 42 CFR §493.1483.
January 2025—The traditional image of a pathologist is often that of a scientist working in a laboratory, handling chemical solutions, or peering through a microscope. Over the past decade, pathologists, including those specializing in cytopathology, have increasingly moved beyond those confines, taking on more prominent roles in patient-facing care. This article explores the various ways cytopathologists are expanding their roles, engaging directly with patients and physicians and positioning themselves at the forefront of the management team.
Automation in coagulation was the topic of a Nov. 11, 2024 roundtable led by CAP TODAY publisher Bob McGonnagle. Put it on a line or on a dedicated automation platform? Seven participants talked about that and about cybersecurity, viscoelastic testing, and the labor shortage, among other things.
